Stoke Therapeutics Inc (FRA:0GT) Stock Price, Trades & News

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	158.71
Equity-to-Asset	0.88
Debt-to-Equity	0.01
Debt-to-EBITDA	-0.01
Interest Coverage	No Debt
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	22.72	Distress Grey Safe
Beneish M-Score	29.46	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	113.7
	3-Year EBITDA Growth Rate	50.6
	3-Year EPS without NRI Growth Rate	64.1
	3-Year Book Growth Rate	8.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-139.78

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	40.4
	9-Day RSI	48.74
	14-Day RSI	50.34
	3-1 Month Momentum %	-5.79
	6-1 Month Momentum %	-7.11
	12-1 Month Momentum %	64.73

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	7.69
	Quick Ratio	7.69
	Cash Ratio	6.98
	Days Sales Outstanding	88.69

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-14.3
	Shareholder Yield %	-3.9

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Operating Margin %	-809.69
	Net Margin %	-753.6
	EBITDA Margin %	-803.37
	FCF Margin %	-656.06
	OCF Margin %	-646.24
	ROE %	-59.88
	ROA %	-51.96
	ROIC %	-197.03
	3-Year ROIIC %	78.16
	ROC (Joel Greenblatt) %	-3470.1
	ROCE %	-62.77
	Moat Score	5
	Tariff Resilience Score	6

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	67.07
	PS Ratio	72.43
	PB Ratio	5.81
	Price-to-Tangible-Book	5.8
	EV-to-EBIT	-7.99
	EV-to-EBITDA	-8.05
	EV-to-Forward-EBITDA	-7.01
	EV-to-Revenue	64.67
	EV-to-Forward-Revenue	58.54
	EV-to-FCF	-9.87
	Price-to-GF-Value	3.34
	Price-to-Net-Current-Asset-Value	7.33
	Price-to-Net-Cash	8.22
	Earnings Yield (Greenblatt) %	-12.52
	FCF Yield %	-8.71

Financials (Next Earnings Date:2026-11-04 Est.)

Annual Quarterly TTM

FRA:0GT's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Stoke Therapeutics Inc Executives

Details

GF Value™: €7.98

FRA:0GT

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with 0GT. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	23.737
	EPS (TTM) (€)	-2.898
	Beta	1.7049
	3-Year Sharpe Ratio	0.94
	3-Year Sortino Ratio	2.41
	Volatility %	57.58
	14-Day RSI	50.34
	14-Day ATR (€)	0.554155
	20-Day SMA (€)	26.15
	12-1 Month Momentum %	64.73
	52-Week Range (€)	15.4 - 32.8
	Shares Outstanding (Mil)	64.53

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	3
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Stoke Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Stoke Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-04 16:30	In 79 days
Third quarter earnings results for 2026	2026-11-04	In 78 days
e Canaccord Genuity 46th Annual Growth Conference	2026-08-12 11:00	27.46 (+0.00%)
Second quarter earnings conference call for 2026	2026-08-03 16:30	25.89 (+0.00%)
Second quarter earnings results for 2026	2026-08-03	25.89 (+0.00%)
Guidance call for 2026	2026-06-08 10:40	25.30 (+0.00%)
Guidance call for 2026	2026-06-04 09:20	24.23 (+0.00%)
General meeting for 2026	2026-06-03 09:00	25.67 (+0.00%)
First quarter earnings conference call for 2026	2026-05-07 16:30	27.72 (+0.00%)
First quarter earnings results for 2026	2026-05-07	27.72 (+0.00%)

Show

Entries

Stoke Therapeutics Inc Frequently Asked Questions

What is Stoke Therapeutics Inc(FRA:0GT)'s stock price today?

The current price of FRA:0GT is €26.62. The 52 week high of FRA:0GT is €32.80 and 52 week low is €15.40.

When is next earnings date of Stoke Therapeutics Inc(FRA:0GT)?

The next earnings date of Stoke Therapeutics Inc(FRA:0GT) is 2026-11-04 Est..

Does Stoke Therapeutics Inc(FRA:0GT) pay dividends? If so, how much?

Stoke Therapeutics Inc(FRA:0GT) does not pay dividend.

Press Release

	Subject	Date
	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	2026-08-18
	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference	2026-08-05
	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates	2026-08-03
	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates	2026-07-27
	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	2026-07-16
	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer	2026-07-13
	Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	2026-06-30
	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	2026-06-16
	Stoke Therapeutics to Present at Upcoming Investor Conferences in June	2026-05-28
	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	2026-05-18

10/Page

Articles on Stoke Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.